OBJECTIVES: Intravitreal injections are an important treatment options for patients with various ophthalmologic diseases in Austria. There is a lack of data on the real-life use of intravitreal injections in Austria.  METHODS: A standardized questionnaire on practice patterns was developed in cooperation with the Austrian Society of ophthalmologic surgeons. The survey was distributed among treating ophthalmologists and results were compared to data from the Austrian ministry of health an prevalence-adjusted results from a landmark study in intravitreal injections.   RESULTS: The response rate to the survey was 100%. Twenty-six centers across Austria participated and reported a cumulative number of 30,124 patients treated with intravitreal injections in 2010. The Austrian ministry of health reports 30,733 intravitreal injections in 2010.   Despite the fact that we have covered more than 98% of cases in our survey, the disparities across different Austrian counties became apparent, from the province Burgenland with only 17% of patients receiving intravitreal injections to the province of Vienna, where 44% of patients received adequate treatment as per the CATT study. Based on a prevalence rate of 0.162%, 13,550 cases of wet AMD are expected in Austria. As there is currently no other treatment option for wet AMD than intravitreal injections and a recent study found the optimal dosing frequency to be seven injections per year, the number of intravitreal injections should be much higher - 94,800 injections are expected if every patient is treated according to the finding from the CATT study, namely 7 injections per affected eye per year. As both eyes are affected in most patients, the number should be even higher.  CONCLUSIONS: More research is needed to increase information and transparency around the  epidemiology of diseases treated by intravitreal injection and the real-life injection rates in Austria.